IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice

Journal of Experimental Medicine

Volumn 203, Issue 6, 2006, Pages 1391-1397

  Hanada, Toshikatsu ^a,b   Kobayashi, Takashi ^a   Chinen, Takatoshi ^a   Saeki, Kazuko ^a   Takaki, Hiromi ^a   Koga, Keiko ^a   Minoda, Yasumasa ^a   Sanada, Takahito ^a   Yoshioka, Tomoko ^a   Mimata, Hiromitsu ^b   Kato, Seiya ^c   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; PROTEIN P53; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; CARRIER PROTEIN; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; SOCS1 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; COLITIS; COLON CANCER; COLON TUMOR; COLORECTAL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; INTERFERON TYPE II; MICE; MICE, KNOCKOUT; NF-KAPPA B; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33745025705     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20060436     Document Type: Article

References (27)

1. Itzkowitz, S.H., and X. Yio. 2004. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287:G7-G17.
2. Oshima, M., and M.M. Taketo. 2002. COX selectivity and animal models for colon cancer. Curr. Pharm. Des. 8:1021-1034.
3. Greten, F.R., L. Eckmann, T.F. Greten, J.M. Park, Z.W. Li, L.J. Egan, M.F. Kagnoff , and M. Karin. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118:285-296.
4. Pikarsky, E., R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun, and Y. Ben-Neriah. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466.
5. Fiocchi, C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115:182-205.
6. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4:1169-1176.
7. Mansell, A., R. Smith, S.L. Doyle, P. Gray, J.E. Fenner, P.J. Crack, S.E. Nicholson, D.J. Hilton, L.A. O'neill, and P.J. Hertzog. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7:148-155.
8. Chinen, T., T. Kobayashi, H. Ogata, G. Takaesu, H. Takaki, M. Hashimoto, H. Yagita, H. Nawata, and A. Yoshimura. 2006. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology. 130:373-388.
9. Weniger, M.A., I. Melzner, C.K. Menz, S. Wegener, A.J. Bucur, K. Dorsch, T. Mattfeldt, T.F. Barth, and P. Moller. 2006. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. In press.
10. Yoshikawa, H., K. Matsubara, G.S. Qian, P. Jackson, J.D. Groopman, J.E. Manning, C.C. Harris, and J.G. Herman. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29-35.
11. Lin, S.Y., K.T. Yeh, W.T. Chen, H.C. Chen, S.T. Chen, H.Y. Chiou, and J.G. Chang. 2004. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol. Rep. 11:341-348.
12. Fujitake, S., K. Hibi, O. Okochi, Y. Kodera, K. Ito, S. Akiyama, and A. Nakao. 2004. Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J. Gastroenterol. 39:120-124.
13. Rottapel, R., S. Ilangumaran, C. Neale, J. La Rose, J.M. Ho, M.H. Nguyen, D. Barber, P. Dubreuil, and P. de Sepulveda. 2002. The tumor suppressor activity of SOCS-1. Oncogene. 21:4351-4362.
14. Kamio, M., T. Yoshida, H. Ogata, T. Douchi, Y. Nagata, M. Inoue, M. Hasegawa, Y. Yonemitsu, and A. Yoshimura. 2004. SOCS1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. Oncogene. 23:3107-3115.
15. Yoshida, T., H. Ogata, M. Kamio, A. Joo, H. Shiraishi, Y. Tokunaga, M. Sata, H. Nagai, and A. Yoshimura. 2004. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. Exp. Med. 199:1701-1707.
16. Hanada, T., H. Yoshida, S. Kato, K. Tanaka, K. Masutani, J. Tsukada, Y. Nomura, H. Mimata, M. Kubo, and A. Yoshimura. 2003. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity. 19:437-450.
17. Morin, P.J., A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K.W. Kinzler. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787-1790.
18. Bromberg, J.F., M.H. Wrzeszczynska, G. Devgan, Y. Zhao, R.G. Pestell, C. Albanese, and J.E. Darnell Jr. 1999. Stat3 as an oncogene. Cell. 98:295-303.
19. Yu, H.G., L.L. Yu, Y. Yang, H.S. Luo, J.P. Yu, J.J. Meier, H. Schrader, A. Bastian, W.E. Schmidt, and F. Schmitz. 2003. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology. 65:37-45.
20. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S.I. Koh, T. Kimura, S.J. Green, et al. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science. 263:1612-1615.
21. Blanco, J.C., C. Contursi, C.A. Salkowski, D.L. DeWitt, K. Ozato, and S.N. Vogel. 2000. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J. Exp. Med. 191:2131-2144.
22. Gupta, R.A., and R.N. Dubois. 2001. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer. 1:11-21.
23. Hussain, S.P., L.J. Hofseth, and C.C. Harris. 2003. Radical causes of cancer. Nat. Rev. Cancer. 3:276-285.
24. Janne, P.A., and R.J. Mayer. 2000. Chemoprevention of colorectal cancer. N. Engl. J. Med. 342:1960-1968.
25. Ambs, S., W.P. Bennett, W.G. Merriam, M.O. Ogunfusika, S.M. Oser, A.M. Harrington, P.G. Shields, E. Felley-Bosco, S.P. Hussain, and C.C. Harris. 1999. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst. 91:86-88.
26. Hussain, S.P., P. Amstad, K. Raja, S. Ambs, M. Nagashima, W.P. Bennett, P.G. Shields, A.J. Ham, J.A. Swenberg, A.J. Marrogi, and C.C. Harris. 2000. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60:3333-3337.
27. Ishitsuka, T., H. Kashiwagi, and F. Konishi. 2001. Microsatellite instability in inflamed and neoplastic epithelium in ulcerative colitis. J. Clin. Pathol. 54:526-532.